A phase 3 open-label trial evaluating the safety, tolerability and immunogenicity of a 13-valent pneumococcal conjugate vaccine in older infants and children who are naive to previous vaccination with pneumococcal conjugate vaccine

Trial Profile

A phase 3 open-label trial evaluating the safety, tolerability and immunogenicity of a 13-valent pneumococcal conjugate vaccine in older infants and children who are naive to previous vaccination with pneumococcal conjugate vaccine

Completed
Phase of Trial: Phase III

Latest Information Update: 17 Feb 2015

At a glance

  • Drugs Pneumococcal 13-valent CRM197 vaccine conjugate (Primary)
  • Indications Pneumococcal infections
  • Focus Pharmacodynamics; Registrational
  • Sponsors Wyeth
  • Most Recent Events

    • 14 Aug 2012 Actual initiation date changed from 1 May 2007 to 1 Jul 2007 as reported by ClinicalTrials.gov.
    • 11 Jun 2009 Results presented at the 27th Annual Meeting of the European Society for Pediatric Infectious Diseases (ESPID), according to a Wyeth media release.
    • 30 Jul 2008 Trial centers updated from NCT.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top